Search results
Harry Mond
Job title: Associate Professor
Author
Author(s):
Somsupha Kanjanauthai
,
Kabir Bhasin
,
Luigi Pirelli
,
et al
Added:
3 years ago
Transcatheter aortic valve replacement (TAVR) has been established as a therapeutic option for patients with severe symptomatic aortic stenosis who are considered to be of intermediate, high or prohibitive surgical risk.1–5 As a result of favorable TAVR outcomes and substantial improvements in transcatheter heart valve (THV) technologies and implantation techniques, the feasibility of broadening…
View more
Christoph Hammerstingl
Job title: Head of the department of Internal Medicine and Cardiology
Author
Author(s):
James Gammie
Added:
2 years ago
In this short interview, Dr James Gammie (University of Maryland Medical Center, MD, US) discusses the findings from surgical trial assessing the benefit of concomitant tricuspid repair during mitral valve surgery. The trial, presented at AHA 2021, demonstrated that at 2 years, TA had no impact on MACCE, survival, or QOL.
Discussion Points
1. Reasoning for this Study
2. Study Design and…
View more
Pier D Lambiase
Job title: Consultant Cardiologist
Author
Ghada Mikhail
Research Area(s) / Expertise:
Job title: Consultant cardiologist
Author
TAVR Optimization
Author(s):
Saima Siddique
,
Resha Khanal
,
Amit N Vora
,
et al
Added:
1 year ago
Article
Author(s):
Michael N Young
,
Sammy Elmariah
Added:
3 years ago
Severe aortic valve stenosis (AS) is chronic, progressive illness that confers significant morbidity and mortality. Once symptomatic, patients with severe AS will ultimately succumb to the disease if it is not promptly corrected.1 Historically, surgical aortic valve replacement (SAVR) served as the exclusive therapeutic option to correct this mechanical problem.2 However, in 2002, Alain Cribier…
View more
Author(s):
Firas Zahr
Added:
2 years ago
In this video interview, Dr Firas Zahr (OHSU Hospital, Portland, OR, US) outlines the 30-day outcomes of the Intrepid TMVR Early Feasibility Study, originally presented at TCT 2021. This was a prospective multicenter trial, designed to study the feasibility of the Intrepid TMVR System. At 30 days, findings show favourable haemodynamics and an improved NYHA class in patients with mitral…
View more
MXR for Cardiology
Author(s):
David Bloom
,
Michael K Southworth
,
Jonathan R Silva
,
et al
Added:
1 year ago
Article